Chih-Chun Chang

Affiliations: 
2017-2019 National Tsing Hua University, Hsinchu City, Taiwan, ROC 
Google:
"Chih-Chun Chang"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Wang LH, Chang CC, Cheng CY, et al. (2022) MCRS1 Expression Regulates Tumor Activity and Affects Survival Probability of Patients with Gastric Cancer. Diagnostics (Basel, Switzerland). 12
Huang CP, Liu LC, Chang CC, et al. (2021) Intratumoral xenogeneic tissue-specific cell immunotherapy inhibits tumor growth by increasing antitumor immunity in murine triple negative breast and pancreatic tumor models. Cancer Letters
Song JS, Chang CC, Wu CH, et al. (2021) A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment. Proceedings of the National Academy of Sciences of the United States of America. 118
Chang CC, Dinh TK, Lee YA, et al. (2020) Nanoparticle Delivery of MnO2 and Anti-angiogenic Therapy to Overcome Hypoxia-Driven Tumor Escape and Suppress Hepatocellular Carcinoma. Acs Applied Materials & Interfaces
Huang KW, Hsu FF, Qiu JT, et al. (2020) Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer. Science Advances. 6: eaax5032
Sung YC, Jin PR, Chu LA, et al. (2019) Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies. Nature Nanotechnology
Sung YC, Liu YC, Chao PH, et al. (2018) Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. Theranostics. 8: 894-905
Chen Y, Liu YC, Sung YC, et al. (2017) Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Scientific Reports. 7: 44123
Gao DY, Lin TT, Sung YC, et al. (2015) CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer. Biomaterials. 67: 194-203
See more...